Patents by Inventor Karl Frank Johnson

Karl Frank Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ULINASTATIN POLYPEPTIDES
    Publication number: 20240002472
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 4, 2024
    Inventors: Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
  • Ulinastatin polypeptides
    Patent number: 11725043
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: August 15, 2023
    Assignee: DiaMedica USA Inc.
    Inventors: Rick Pauls, Todd Verdoorn, Karl Frank Johnson, Gregory Thomas Bleck
  • ULINASTATIN POLYPEPTIDES
    Publication number: 20210277090
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventors: Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
  • Ganglioside compositions and methods of use
    Patent number: 7888331
    Abstract: Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: February 15, 2011
    Assignee: Seneb Biosciences, Inc.
    Inventors: Shawn A. Defrees, Karl Frank Johnson, Zhi-Guang Wang